Abstract
In late 2019, a novel coronavirus causing severe acute respiratory syndrome (SARS-CoV-2) emerged in Wuhan, China and rapidly spread throughout the world causing coronavirus disease (COVID-19). End-stage kidney disease (ESKD) populations are vulnerable group with high mortality when contracted COVID-19. We aimed to determine the effects of vaccine on the severity and mortality rate of COVID-19 infection among ESKD population in Malaysia.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
